Frédéric Baron

13.6k citations

220 papers · 7.2k indexed · 1 hit paper · h-index 40

Impact in

Hematology top 0.05%
- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
Transplantation top 0.5%
- Renal Transplantation Outcomes and Treatments

Papers in ⓘ

Hematology 178
- Hematopoietic Stem Cell Transplantation 151
- Acute Myeloid Leukemia Research 63
- Multiple Myeloma Research and Treatments 12
Genetics 41
- Mesenchymal stem cell research 23

Co-authors: Rainer Storb (34 shared papers)Brenda M. Sandmaier (26 shared papers)David G. Maloney (20 shared papers)Michael B. Maris (14 shared papers)Mohamed L. Sorror (16 shared papers)Barry E. Storer (14 shared papers)Yves Béguin (100 shared papers)Arnon Nagler (36 shared papers)
Journals: Blood (29 papers)Biology of Blood and Marrow Transplantation (19 papers)Bone Marrow Transplantation (16 papers)Haematologica (11 papers)Frontiers in Immunology (8 papers)
Partner nations: Belgium United States France

In The Last Decade

Frédéric Baron

210 papers receiving 7.1k citations

Hit Papers

align trajectories log scale

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT 2005 · 2.0k citations

Peers

Countries citing papers authored by Frédéric Baron

Since Specialization

Citations

This map shows the geographic impact of Frédéric Baron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frédéric Baron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frédéric Baron more than expected).

Fields of papers citing papers by Frédéric Baron

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frédéric Baron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frédéric Baron. The network helps show where Frédéric Baron may publish in the future.

Co-authors

The 25 scholars most cited alongside Frédéric Baron, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Frédéric Baron Line = papers co-authored together Frédéric Baron links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 220 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT Blood ·Mohamed L. Sorror, Michael B. Maris, Rainer Storb, Frédéric Baron, Brenda M. Sandmaier, David G. Maloney, Barry E. Storer Hit paper breakdown →	2005	1977
2	Comorbidity and Disease Status–Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation Journal of Clinical Oncology ·Mohamed L. Sorror, Brenda M. Sandmaier, Barry E. Storer, Michael B. Maris, Frédéric Baron, David G. Maloney, Bart L. Scott, H. Joachim Deeg, Frederick R. Appelbaum, Rainer Storb	2007	290
3	Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning Journal of Clinical Oncology ·Frédéric Baron, Michael B. Maris, Brenda M. Sandmaier, Barry E. Storer, Mohamed L. Sorror, Razvan Diaconescu, Ann E. Woolfrey, Thomas R. Chauncey, Mary E.D. Flowers, Marco Mielcarek, David G. Maloney, Rainer Storb	2005	262
4	Hematopoietic cell transplantation (HCT)-specific-comorbidity index: A new tool for risk assessment before allogeneic HCT Biology of Blood and Marrow Transplantation ·Mohamed L. Sorror, Michael B. Maris, Rainer Storb, Frédéric Baron, Brenda M. Sandmaier, David G. Maloney, Sarah Barry	2005	199
5	Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning Blood ·Frédéric Baron, Jennifer E. Baker, Rainer Storb, Theodore A. Gooley, Brenda M. Sandmaier, Michael B. Maris, David G. Maloney, Shelly Heimfeld, Dmitrij Oparin, Eustacia Zellmer, Jerald P. Radich, F. Carl Grumet, Karl G. Blume, Thomas R. Chauncey, Marie-Térèse Little	2004	190
6	Cotransplantation of Mesenchymal Stem Cells Might Prevent Death from Graft-versus-Host Disease (GVHD) without Abrogating Graft-versus-Tumor Effects after HLA-Mismatched Allogeneic Transplantation following Nonmyeloablative Conditioning Biology of Blood and Marrow Transplantation ·Frédéric Baron, Chantal Lechanteur, Évelyne Willems, France Bruck, Étienne Baudoux, Laurence Seidel, Jean-François Vanbellinghen, Kaoutar Hafraoui, Marie Lejeune, André Gothot, Georges Fillet, Yves Béguin	2010	160
7	Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT Bone Marrow Transplantation ·Panagiotis Tsirigotis, Michael Byrne, Christoph Schmid, Frédéric Baron, Fabio Ciceri, Jordi Esteve, Norbert Claude Gorin, Sebastian Giebel, Mohamad Mohty, Bipin N. Savani, Arnon Nagler	2016	144
8	Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation Leukemia ·Frédéric Baron, Myriam Labopin, Dietger Niederwieser, S. Vigouroux, Jan J. Cornelissen, Christer Malm, Lars L. Vindeløv, Didier Blaise, Jeroen J. W. M. Janssen, Eefke Petersen, Gèrard Socié, Arnon Nagler, Vanderson Rocha, Mohamad Mohty	2012	134
9	Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning Leukemia ·Frédéric Baron, Brenda M. Sandmaier	2006	122
10	Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo Science Translational Medicine ·Julia Cuende, Stéphanie Liénart, Olivier Dedobbeleer, Bas van der Woning, Gitte De Boeck, Julie Stockis, Caroline Huygens, Didier Colau, Joan Somja, Philippe Delvenne, Muriel Hannon, Frédéric Baron, Laure Dumoutier, Jean‐Christophe Renauld, Hans de Haard, Michael Saunders, Pierre G. Coulie, Sophie Lucas	2015	121
11	Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation Cancer ·Sebastian Giebel, Anna Czyż, Oliver G. Ottmann, Frédéric Baron, Éolia Brissot, Fabio Ciceri, Jan J. Cornelissen, Jordi Esteve, Norbert Claude Gorin, Bipin N. Savani, Christoph Schmid, Mohamad Mohty, Arnon Nagler	2016	113
12	Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study Journal of Clinical Oncology ·Roni Shouval, Myriam Labopin, Ori Bondi, Hila Mishan‐Shamay, Avichai Shimoni, Fabio Ciceri, Jordi Esteve, Sebastian Giebel, Norbert Claude Gorin, Christoph Schmid, Emmanuelle Polge, Mahmoud Aljurf, Nicolaus Kröger, Charles Craddock, Andrea Bacigalupo, Jan J. Cornelissen, Frédéric Baron, Ron Unger, Arnon Nagler, Mohamad Mohty	2015	105
13	Infusion of mesenchymal stromal cells after deceased liver transplantation: A phase I–II, open-label, clinical study Journal of Hepatology ·Olivier Detry, Morgan Vandermeulen, Marie‐Hélène Delbouille, Joan Somja, Noëlla Blétard, Alexandra Briquet, Chantal Lechanteur, Olivier Giet, Étienne Baudoux, Muriel Hannon, Frédéric Baron, Yves Béguin	2017	104
14	Anti-thymocyte globulin as graft- versus -host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation Haematologica ·Frédéric Baron, Mohamad Mohty, Didier Blaise, Gèrard Socié, Myriam Labopin, Jordi Esteve, Fabio Ciceri, Sebastian Giebel, Norbert Claude Gorin, Bipin N. Savani, Christoph Schmid, Arnon Nagler	2016	96
15	Mesenchymal Stromal Cells: A New Tool against Graft-versus-Host Disease? Biology of Blood and Marrow Transplantation ·Frédéric Baron, Rainer Storb	2011	82
16	Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma Oncotarget ·Marilène Binsfeld, Joséphine Muller, Virginie Lamour, Kim De Veirman, Hendrik De Raeve, Akeila Bellahcène, Els Van Valckenborgh, Frédéric Baron, Yves Béguin, Jo Caers, Roy Heusschen	2016	82
17	Infusion of third-party mesenchymal stromal cells after kidney transplantation: a phase I-II, open-label, clinical study Kidney International ·Pauline Erpicum, Laurent Weekers, Olivier Detry, Catherine Bonvoisin, Marie‐Hélène Delbouille, Céline Grégoire, Étienne Baudoux, Alexandra Briquet, Chantal Lechanteur, Gianni Maggipinto, Joan Somja, Hans Pottel, Frédéric Baron, François Jouret, Yves Béguin	2018	80
18	Factors Associated With Outcomes in Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning After Failed Myeloablative Hematopoietic Cell Transplantation Journal of Clinical Oncology ·Frédéric Baron, Rainer Storb, Barry E. Storer, Michael B. Maris, Dietger Niederwieser, Judith A. Shizuru, Thomas R. Chauncey, Benedetto Bruno, Stephen J. Forman, Peter A. McSweeney, Richard T. Maziarz, Michael A. Pulsipher, Edward Agura, James C. Wade, Mohamed L. Sorror, David G. Maloney, Brenda M. Sandmaier	2006	72
19	Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning Bone Marrow Transplantation ·E. Willems, Frédéric Baron, Laurence Seidel, Pascale Frère, Georges Fillet, Y Beguin	2009	65
20	Xenogeneic Graft-Versus-Host Disease in Humanized NSG and NSG-HLA-A2/HHD Mice Frontiers in Immunology ·Grégory Ehx, Joan Somja, Hans-Jörg Warnatz, Caroline Ritacco, Muriel Hannon, Loïc Delens, Gilles Fransolet, Philippe Delvenne, Joséphine Muller, Yves Béguin, Hans Lehrach, Ludovic Belle, Stéphanie Humblet‐Baron, Frédéric Baron	2018	63

About Frédéric Baron

Frédéric Baron is a scholar working on Hematology, Genetics, Immunology, Transplantation and Oncology, having authored 220 papers that have together received 7.2k indexed citations. Recurring topics across this work include Hematopoietic Stem Cell Transplantation (151 papers), Acute Myeloid Leukemia Research (63 papers), Immune Cell Function and Interaction (50 papers), T-cell and B-cell Immunology (38 papers), Acute Lymphoblastic Leukemia research (37 papers), Mesenchymal stem cell research (23 papers), CAR-T cell therapy research (15 papers) and Multiple Myeloma Research and Treatments (12 papers). The work is most often cited by research in Hematology (5.2k citations), Transplantation (512 citations), Genetics (1.4k citations), Immunology (1.9k citations) and Oncology (1.7k citations). Frédéric Baron has collaborated with scholars based in Belgium, United States and France. Frequent co-authors include Rainer Storb, Brenda M. Sandmaier, David G. Maloney, Michael B. Maris, Mohamed L. Sorror, Barry E. Storer, Yves Béguin, Arnon Nagler, Mohamad Mohty and Georges Fillet. Their work appears in journals such as Blood, Biology of Blood and Marrow Transplantation, Bone Marrow Transplantation, Haematologica and Frontiers in Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact